Abstract
Since the last 4 decades, Bedaquiline has been the first drug discovered as a new kind of anti-tubercular agent and received FDA approval in December 2012 to treat pulmonary multi-drug resistance tuberculosis (MDR-TB). It demonstrates excellent efficacy against MDR-TB by effectively inhibiting mycobacterial ATP synthase. In addition to these apparent assets of Bedaquiline, potential disadvantages of Bedaquiline include inhibition of the hERG (human Ether-à-go-related gene; KCNH2), potassium channel (concurrent risk of cardiac toxicity), and risk of phospholipidosis due to its more lipophilic nature. To assist the effective treatment of MDR-TB, highly active Bedaquiline analogs that display a better safety profile are urgently needed. A structure-based virtual screening approach was used to address the toxicity problems associated with Bedaquiline. Among the virtually screened compound, CID 15947587 had significant docking affinity (− 5.636 kcal/mol) and highest binding free energy (ΔG bind − 85.2703 kcal/mol) towards the Mycobacterial ATP synthase enzyme with insignificant cardiotoxicity and lipophilicity. During MD simulation studies (50 ns), the molecule optimizes its conformation to fit better the active receptor site justifying the binding affinity. The obtained results showed that CID15947587 could be a useful template for further optimizing the MDR-TB inhibitor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
(1974) Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 2(7889):1100–1106
(2017) Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2018-4. Maestro-Desmond Interoperability Tools, Schrödinger, New York, NY, 2018-4
Amala M, Rajamanikandan S, Prabhu D, Surekha K, Jeyakanthan J (2019) Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches. J Biomol Struct Dyn 37(2):394–410. https://doi.org/10.1080/07391102.2018.1427633
Bhowmick S, AlFaris NA, AlTamimi JZ, AlOthman ZA, Aldayel TS, Wabaidur SM, Islam MA (2020) Screening and analysis of bioactive food compounds for modulating the CDK2 protein for cell cycle arrest: multi-cheminformatics approaches for anticancer therapeutics. J Mol Struct. https://doi.org/10.1016/j.molstruc.2020.128316
Bochevarov AD, Harder E, Hughes TF, Greenwood JR, Braden DA, Philipp DM, Rinaldo D, Hall MD, Zhang J, Friesner RA (2013) Jaguar: a high-performance quantum chemistry software program with strengths in life and materials sciences. Int J Quantum Chem 113(18):2110–2142. https://doi.org/10.1002/qua.24481
Casalvieri KA, Matheson CJ, Backos DS, Reigan P (2020) Molecular docking of substituted pteridinones and pyrimidines to the ATP-binding site of the N-terminal domain of RSK2 and associated MM/GBSA and molecular field datasets. Data Brief 29:105347. https://doi.org/10.1016/j.dib.2020.105347
Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ (2010) Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov 5(6):597–607. https://doi.org/10.1517/17460441.2010.484460
Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56(6):3271–3276. https://doi.org/10.1128/AAC.06126-11
Dooley KE, Nuermberger EL, Diacon AH (2013) Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS 6:579–585. https://doi.org/10.1097/COH.0000000000000009
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47(7):1739–1749. https://doi.org/10.1021/jm0306430
Ganesan MS, Raja KK, Murugesan S, Kumar BK, Rajagopal G, Thirunavukkarasu S (2020) Synthesis, biological evaluation, molecular docking, molecular dynamics and DFT studies of quinolone–fluoroproline amide hybrids. J Mol Struct. https://doi.org/10.1016/j.molstruc.2020.128360
Guillemont J, Meyer C, Poncelet A, Bourdrez X, Andries K (2011) Diarylquinolines, synthesis pathways and quantitative structure–activity relationship studies leading to the discovery of TMC207. Future Med Chem 3(11):1345–1360. https://doi.org/10.4155/fmc.11.79
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750–1759. https://doi.org/10.1021/jm030644s
https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf?ua=1. Assessed on 7/11/2020
https://www.who.int/tb/areas-of-work/drug-resistant-tb/global-situation/en/
Jagadeb M, Rath SN, Sonawane A (2019) In silico discovery of potential drug molecules to improve the treatment of isoniazid-resistant Mycobacterium tuberculosis. J Biomol Struct Dyn 37(13):3388–3398. https://doi.org/10.1080/07391102.2018.1515116
Jin Z, Wang Y, Yu XF, Tan QQ, Liang SS, Li T, Zhang H, Shaw PC, Wang J, Hu C (2020) Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: molecular dynamics simulation and MM-GBSA calculation. Comput Biol Chem 85:107241. https://doi.org/10.1016/j.compbiolchem.2020.107241
Jordaan MA, Ebenezer O, Damoyi N, Shapi M (2020) Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. Heliyon 6(8):e04642. https://doi.org/10.1016/j.heliyon.2020.e04642
Mahajan R (2013) Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res 3(1):1–2. https://doi.org/10.4103/2229-516X.112228
Maitra A, Bates S, Shaik M, Evangelopoulos D, Abubakar I, McHugh TD, Lipman M, Bhakta S (2016) Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. Br Med Bull 118(1):138–148. https://doi.org/10.1093/bmb/ldw019
Mesens N, Verbeeck J, Rouan M, Vanparys P (2007) Elucidating the role of M2 in the preclinical safety profile of TMC207. Abstract on the 38th Union World Conference on Lung Health, Cape Town South Africa
Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, Ferrara G, Cirillo DM, Gori A, Matteelli A, Spanevello A, Codecasa LR, Raviglione MC, SMIRA/TBNET Study Group (2007) Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 30(4):623–626. https://doi.org/10.1183/09031936.00077307
Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC (2008) Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359(6):563–574. https://doi.org/10.1056/NEJMoa0800106
Murray JS, Politzer P (2011) The electrostatic potential: an overview. Wiley Interdiscip Rev Comput Mol Sci 1(2):153–163
Nath H, Ryoo S (2013) First- and second-line drugs and drug resistance. Tuberc Curr Issues Diagn Manag. https://doi.org/10.5772/54960
Panwar U, Singh SK (2020) Atom-based 3D-QSAR, molecular docking, DFT, and simulation studies of acylhydrazone, hydrazine, and diazene derivatives as IN-LEDGF/p75 inhibitors. Struct Chem. https://doi.org/10.1007/s11224-020-01628-3
Patel H, Dhangar K, Sonawane Y, Surana S, Karpoormath R, Thapliyal N, Jagtap R (2018) In search of selective 11β-HSD type 1 inhibitors without nephrotoxicity: an approach to resolve the metabolic syndrome by virtual based screening. Arab J Chem 11(2):221–232. https://doi.org/10.1016/j.arabjc.2015.08.003
Patel H, Pawara R, Pawara K, Ahmed F, Shirkhedkar A, Surana S (2019) A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity. Tuberculosis 117:79–84. https://doi.org/10.1016/j.tube.2019.06.005
Patel HM, Shaikh M, Ahmad I, Lokwani D, Surana SJ (2020a) BREED based de novo hybridization approach: generating novel T790M/C797S-EGFR tyrosine kinase inhibitors to overcome the problem of mutation and resistance in non-small cell lung cancer (NSCLC). J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1754918 (published online ahead of print)
Patel HM, Ahmad I, Pawara R, Shaikh M, Surana SJ (2020b). J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1734092
Schrödinger Release (2008) Protein preparation wizard. Epik Schrödinger, LLC, New York
Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440(7083):463–469. https://doi.org/10.1038/nature04710
Saxena S, Renuka J, Yogeeswari P, Sriram D (2014) Discovery of novel mycobacterial DNA gyrase B inhibitors: in silico and in vitro biological evaluation. Mol Inform 33(9):597–609. https://doi.org/10.1002/minf.201400058
Seung KJ, Keshavjee S, Rich ML (2015) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 5(9):a017863. https://doi.org/10.1101/cshperspect.a017863
Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues M, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP (2007) Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13(3):380–387. https://doi.org/10.3201/eid1303.061400
Svensson EM, Murray S, Karlsson MO, Dooley KE (2015) Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 70(4):1106–1114. https://doi.org/10.1093/jac/dku504
Treatment of Patients with MDR-TB (2014) Briefing document, TMC 207 (bedaquiline). Anti-infective Drugs Advisory Committee, NDA pp 204–384
Vijayakumar B, Parasuraman S, Raveendran R, Velmurugan D (2014) Identification of natural inhibitors against angiotensin I converting enzyme for cardiac safety using induced fit docking and MM-GBSA studies. Pharmacogn Mag 10(Suppl 3):S639–S644. https://doi.org/10.4103/0973-1296.139809
Vistoli G, Pedretti A, Testa B (2008) Assessing drug-likeness—what are we missing? Drug Discov Today 13(7–8):285–294. https://doi.org/10.1016/j.drudis.2007.11.007
Funding
The authors would like to thank ‘Indian Council of Medical Research (ICMR) Ministry of Health and Family Welfare, Department of Health Research Govt. of India’ (Grant no. ISRM/12(11)/2019) for funding the project.
Author information
Authors and Affiliations
Contributions
Author IA and HP was involved in the idea generation and performing the computational chemistry work. HJ, YS have contributed in the molecular dynamic simulation study. RG and VJ contributed for the manuscript writing and grammatical check.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no actual or potential conflict of interest including any financial, personal, or other relationships with other people or organizations.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ahmad, I., Jadhav, H., Shinde, Y. et al. Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors. In Silico Pharmacol. 9, 23 (2021). https://doi.org/10.1007/s40203-021-00086-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40203-021-00086-x